Clinical Enterprise, Inc., a Eurofins Scientific Company, has launched a new partnership with Ginkgo Bioworks to support Operation Expanded Testing Program with the U.S. Department of Health and Human Services and Department of Defense. Operation Expanded Testing provides fully federally funded COVID-19 PCR testing to K-12 public and private schools, Historically Black Colleges & Universities, daycare centers, community organizations, congregate settings, correctional facilities, and underserved communities. The program helps to equip these organizations with testing guidance and resources, promoting equity in COVID-19 testing and mitigation.

Clinical Enterprise and the Eurofins U.S. Clinical Diagnostics team are excited to partner with Ginkgo Bioworks to provide these organizations a fast and reliable solution to help detect asymptomatic infections in order to reduce transmission, prevent outbreaks, and protect vulnerable populations. Throughout the pandemic, Ginkgo Bioworks has supported widespread surveillance testing through its biosecurity and public health effort, Concentric by Ginkgo. Concentric currently provides an integrated COVID-19 testing platform for over 220,000 individuals per week through its programs in K-12 schools, correctional facilities, and airports. Concentric’s involvement will help the organizations already participating in the program to implement testing and will provide the opportunity to expand testing to more sites and organizations.

“Through this collaboration with the incredible team at Eurofins, we can empower community leaders with critical information while helping to keep kids in class and COVID-19 out,” said Matthew McKnight, Ginkgo’s Chief Commercial Officer. “We believe the biosecurity tools provided through this program will support public health across the country.”

To date, Clinical Enterprise has enrolled schools and organizations in 26 states in the northeast and south regions, as well as Washington D.C., Puerto Rico, and U.S. Virgin Islands.

This project has been funded in whole or in part by the U.S. Government under Agreement No. W52P1J-21-9-200. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon.